Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950312 · ClinicalTrials.gov registry record · Phase 2
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
A Phase 2 study of Autoimmune Inner Ear Disease, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01950312 is a Phase 2 study of Autoimmune Inner Ear Disease that has completed, run by Xoma (US). The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01950312, a Phase 2 study of Autoimmune Inner Ear Disease, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
Conditions Studied
Interventions
- DRUG gevokizumab
Study Locations (1)
New York
- Long Island Jewish Medical Center, Hearing & Speech Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950312
The ClinicalTrials.gov registry entry for NCT01950312 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autoimmune Inner Ear Disease appearing as the primary indexed condition, and to 1 intervention - of which gevokizumab is the first listed.
NCT01950312 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01950312 about?
NCT01950312 is a clinical study titled "The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease". The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
What is the current status of trial NCT01950312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-08. Estimated completion is 2015-12.
What conditions does trial NCT01950312 study?
This clinical trial studies the following conditions: Autoimmune Inner Ear Disease.
What interventions are being tested in trial NCT01950312?
The interventions under investigation include: gevokizumab (DRUG).
Who is sponsoring clinical trial NCT01950312?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01950312 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Inner Ear Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.